TABLE 2.

Clinical features of COVID‐19 among affected PD and non‐PD controls (family members)

		PD With COVID‐19 (N = 105)	Controls With COVID‐19 (N = 92)	P Value*	Age‐Adjusted OR [95% CI]**	P Value**
Clinical features	Total reported symptoms	3.4 ± 1.8	3.5 ± 1.8	0.70	—	—
	Fever	74 (70.5%)	67 (72.8%)	0.75	0.85 [0.45–1.61]	0.61
	Cough	62 (59.0%)	55 (59.8%)	1.00	0.91 [0.50–1.63]	0.74
	Shortness of breath	17 (16.2%)	26 (28.3%)	0.06	0.33 [0.15–0.70]	0.004
	Nasal congestion	44 (41.9%)	35 (38.0%)	0.66	1.39 [0.76–2.52]	0.29
	Olfactory dysfunction	17 (16.2%)	17 (18.5%)	0.71	0.78 [0.36–1.67]	0.52
	Gustatory dysfunction	19 (18.1%)	16 (17.4%)	1.00	1.08 [0.51–2.30]	0.84
	Nausea or vomiting	15 (14.3%)	15 (16.3%)	0.70	1.05 [0.47–2.35]	0.91
	Diarrhea	28 (26.7%)	20 (21.7%)	0.74	1.58 [0.80–3.14]	0.19
	Myalgia or arthralgia	35 (33.3%)	30 (32.6%)	1.00	1.14 [0.62–2.11]	0.67
	Fatigue	40 (38.1%)	31 (33.7%)	0.55	1.31 [0.71–2.38]	0.39
	Conjunctivitis	10 (9.5%)	7 (7.6%)	0.80	1.18 [0.42–3.32]	0.75
Pattern of symptoms	Respiratory	50 (47.6%)	52 (56.5%)	0.25	0.64 [0.36–1.14]	0.13
	Gastrointestinal	13 (12.4%)	10 (10.9%)	0.83	1.42 [0.57–3.56]	0.45
	Systemic	22 (21.0%)	11 (12.0%)	0.12	2.05 [0.91–4.59]	0.08
	Unspecific/mild	18 (17.1%)	14 (15.2%)	0.85	1.18 [0.54–2.57]	0.68
	Asymptomatic	2 (1.9%)	5 (5.4%)	0.25	0.27 [0.05–1.50]	0.14
Outcome	Death	6 (5.7%)	7 (7.6%)	0.77	0.45 [0.13–1.53]	0.20
	Hospitalization	18 (17.1%)	25 (27.2%)	0.12	0.41 [0.20–0.86]	0.018

Values are mean ± SD or n (%), significant data are bold‐typed. Between‐group comparisons of clinical features, pattern of symptoms, and outcomes were performed using the unpaired Student’s t test whereas categorical variables were analyzed by the Fisher’s exact test.

^*Given the significant between‐group age difference (Supporting Information Table S2), age‐adjusted ORs.

^**were used to further explore these comparisons (an independent model for each variable/outcome).